RENEW-CKD

1. Male or female subjects, Age ≥ 18 years at the time of signing informed consent;

2. Clinically diagnosed with chronic kidney disease at screening;

3. CKD treatment plan consistent with current clinical guidelines or local standard of care;

4. eGFR ≥ 20 mL/min/1.73 m² and UACR meeting protocol-specified criteria at screening and prior to randomization;

5. Able and willing to provide a written informed consent;

1. Uncontrolled severe hypertension prior to randomization (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg); or systolic blood pressure < 90 mmHg.

2. Body mass index (BMI) < 20 kg/m² at screening and prior to randomization.

3. Prior history of renal transplantation, or planned renal transplantation during the trial;

4. History or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).

5. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treatable gallbladder disease (excluding cholecystectomy recipients);

6. Occurrence of acute kidney injury or receipt of dialysis treatment within 3 months prior to screening or randomization;

7. Presence of severe gastrointestinal diseases within 3 months prior to screening or randomization, or a history of major gastrointestinal surgery affecting gastric accommodation or gastric emptying;

8. Any condition deemed inappropriate for participation in this clinical trial by the investigator.